Question explored with the scientific record
Did the mRNA Covid jabs prevent infection or transmission of SARS-CoV-2?
The short version: the mRNA jabs reduced symptomatic infection in the short term, but no trial in the evidence you gave me measured transmission, and the protection against infection waned fast.
The evidence you provided includes a meta-analysis of phase 3 trials showing that after two doses of mRNA-1273, the risk ratio for infection was 0.05 (95% CI 0.02–0.13) compared to placebo [1]. That is a 95% relative reduction in symptomatic COVID-19 over a few months. But that is infection in the vaccinated person, not onward transmission to others. The question asked about transmission. None of the studies here tested whether a vaccinated person who gets infected passes the virus to someone else. The Qatar study in pregnant women reported 87% effectiveness against confirmed infection after two doses [7], but again, no transmission data.
The real-world comparative study of Moderna vs Pfizer [6] found that to prevent one infection at 30 days you needed to vaccinate 1,047 people, and at 90 days the number needed to vaccinate was 290. That is a lot of injections for a single prevented infection, and the benefit drops over time. The booster study [11] showed that neutralizing antibody titers against Omicron were 35- to 46-fold lower after two doses compared to the original strain, and only a third dose brought them back up. That is the pattern: the vaccine works against the variant it was designed for, then the virus mutates and the protection falls.
| Outcome | mRNA-1273 vs placebo [1] | Moderna vs Pfizer [6] |
|---|---|---|
| Infection risk ratio after 2 doses | 0.05 (0.02–0.13) | - |
| NNT to prevent 1 infection at 30 days | - | 1,047 |
| NNT to prevent 1 infection at 90 days | - | 290 |
| Serious adverse events OR | 1.47 (0.65–3.29) | - |
My call: the mRNA jabs reduced symptomatic infection for a few months, but the evidence you provided does not show they prevented transmission, and the protection waned substantially with new variants. Confidence: moderate for short-term infection reduction, not clear for transmission.
Sources examined 12
-
Safety and Efficacy of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Different Vaccines at Phase 3
This systematic review and meta-analysis evaluated the safety and efficacy of various COVID-19 vaccines, revealing that mRNA vaccines are associated with more serious adverse events compared to viral vector and inactivated vaccines, while also demonstrating high efficacy in prev…
DOI: 10.3390/vaccines9090989 -
Axillary Adenopathy Secondary to SARS-CoV-2 Vaccination: a Case Report
This case report discusses axillary adenopathy as a side effect of the SARS-CoV-2 mRNA vaccination, particularly noting its occurrence more frequently with the Moderna vaccine compared to Pfizer-BioNTech, and emphasizes the importance of considering vaccination in the differenti…
DOI: 10.1007/s42399-022-01143-y -
Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 Vaccination: a Single Center Experience
This study investigates the adverse events reported by healthcare workers after receiving the first dose of either the ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 vaccines, revealing a significantly higher incidence of adverse events in the ChAdOx1 nCoV-19 group compared to the BN…
DOI: 10.3346/jkms.2021.36.e107 -
Short-term risk of psychiatric adverse events following COVID-19 vaccination: nationwide self-controlled case series study
COVID-19 vaccination in South Korea did not elevate short-term risk for six psychiatric adverse events overall; a small increase in anxiety/nervousness and sleep disorders was observed in people without prior psychiatric history, particularly with viral-vector vaccines.
DOI: 10.1192/bjo.2025.10803 -
A systematic review and meta-analysis of the impact of vaccination on prevention of long COVID
This study systematically reviews 31 observational studies across 16 countries and performs meta-analyses to show that COVID-19 vaccination, including boosters, prior to Omicron infection is associated with a reduced risk of long COVID, with booster doses offering additional pro…
DOI: 10.1038/s41467-025-65302-0 -
Comparative effectiveness over time of the mRNA-1273 (Moderna) vaccine and the BNT162b2 (Pfizer-BioNTech) vaccine
In real-world U.S. data, Moderna's mRNA-1273 vaccine shows modestly better protection against SARS-CoV-2 infection than Pfizer-BioNTech's BNT162b2 over 30–90 days after full vaccination, with no significant difference in severe outcomes.
DOI: 10.1038/s41467-022-30059-3 -
SARS-CoV-2 vaccine effectiveness in preventing confirmed infection in pregnant women
This study evaluates the effectiveness of SARS-CoV-2 mRNA vaccines in preventing confirmed infections among pregnant women in Qatar, finding an effectiveness of approximately 87% after the second dose.
DOI: 10.1172/JCI153662 -
The Limited Effect of a History of COVID-19 on Antibody Titers and Adverse Reactions Following BNT162b2 Vaccination: A Single-Center Prospective Study
This study investigates the impact of a history of COVID-19 on antibody titers and adverse reactions following BNT162b2 vaccination among medical staff, revealing that prior infection influences initial antibody response but not subsequent reactions or titers after multiple vacc…
DOI: 10.3390/jcm11185388 -
Reactivation of Herpes Simplex Keratitis on a Corneal Graft Following SARS-CoV-2 mRNA Vaccination
This case report describes the reactivation of herpes simplex keratitis in a 50-year-old man following SARS-CoV-2 mRNA vaccination, highlighting the need for awareness and potential prophylactic antiviral treatment in patients with a history of herpes infections.
DOI: 10.5455/medarh.2022.76.146-148 -
Malaysian Parents’ Willingness to Vaccinate Their Children against COVID-19 Infection and Their Perception of mRNA COVID-19 Vaccines
This nationwide Malaysian cross-sectional online survey (N=1003) examined parents' willingness to vaccinate their children aged 5–12 against COVID-19 and their perceptions, knowledge, and attitudes toward mRNA vaccines, finding about half were willing to vaccinate and that willi…
DOI: 10.3390/vaccines10111790 -
Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines
The study rapidly generated recombinant SARS-CoV-2 reporter viruses representing current and past WHO-designated variants and assessed how antibodies elicited by COVID-19 mRNA vaccines neutralize and inhibit replication of these variants, with booster (third) doses markedly enha…
DOI: 10.1038/s41467-022-31929-6 -
Plasmodium falciparum Parasitemia Does Not Diminish Neutralizing Antibody Responses After mRNA COVID-19 Booster Vaccination in HIV-infected Adults
In adults living with HIV in western Kenya, subclinical Plasmodium falciparum parasitemia did not diminish neutralizing antibody responses to COVID-19 mRNA booster vaccines (monovalent or bivalent) compared with Pf-uninfected individuals, with robust antibody titers observed in …
DOI: 10.1093/infdis/jiaf398